Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype

Citations Over TimeTop 10% of 2016 papers

Abstract

Centrosome-localized mitotic Aurora kinase A (AURKA) facilitates G2/M events. Here we show that AURKA translocates to the nucleus and causes distinct oncogenic properties in malignant cells by enhancing breast cancer stem cell (BCSC) phenotype. Unexpectedly, this function is independent of its kinase activity. Instead, AURKA preferentially interacts with heterogeneous nuclear ribonucleoprotein K (hnRNP K) in the nucleus and acts as a transcription factor in a complex that induces a shift in MYC promoter usage and activates the MYC promoter. Blocking AURKA nuclear localization inhibits this newly discovered transactivating function of AURKA, sensitizing resistant BCSC to kinase inhibition. These findings identify a previously unknown oncogenic property of the spatially deregulated AURKA in tumorigenesis and provide a potential therapeutic opportunity to overcome kinase inhibitor resistance.

Related Papers

• → Causes and consequences of centrosome abnormalities in cancer(2014)360 cited
• → Never tear us apart – the importance of centrosome clustering(2012)87 cited
• → The centrosome and cell proliferation.(2006)32 cited
• → A method of quantifying centrosomes at the single-cell level in human normal and cancer tissue(2019)15 cited
• → Amorphous no longer: the centrosome comes into focus(1999)128 cited